Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations.

[1]  A. Lupu,et al.  A Review of FLT3 Kinase Inhibitors in AML , 2023, Journal of Clinical Medicine.

[2]  Shin-ichiro Takahashi.  Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment , 2023, Hematology reports.

[3]  P. Chiusolo,et al.  Targeting the undruggable: menin inhibitors ante portas , 2023, Journal of Cancer Research and Clinical Oncology.

[4]  John G Doench,et al.  MEN1 mutations mediate clinical resistance to menin inhibition , 2023, Nature.

[5]  S. Armstrong,et al.  The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia , 2023, Nature.

[6]  S. de Botton,et al.  Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia , 2022, Blood.

[7]  Y. Qi,et al.  Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c) , 2022, Blood cancer journal.

[8]  Gary D Bader,et al.  The reactome pathway knowledgebase 2022 , 2021, Nucleic Acids Res..

[9]  S. Armstrong,et al.  The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML , 2021, Blood.

[10]  T. Cierpicki,et al.  Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML with activating FLT3 mutations. , 2020, Blood.

[11]  J. Klco,et al.  Mechanistic insights and potential therapeutic targets for NUP98-rearranged hematologic malignancies. , 2020, Blood.

[12]  S. Armstrong,et al.  Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition. , 2020, Blood.

[13]  M. Heuser,et al.  CDK6 is an essential direct target of NUP98-fusion proteins in acute myeloid leukemia. , 2020, Blood.

[14]  E. Barragán,et al.  Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control? , 2020, Blood reviews.

[15]  D. Reinhardt,et al.  Mutated WT1, FLT3-ITD, and NUP98-NSD1 Fusion in Various Combinations Define a Poor Prognostic Group in Pediatric Acute Myeloid Leukemia , 2019, Journal of oncology.

[16]  T. Cierpicki,et al.  Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction. , 2018, Journal of medicinal chemistry.

[17]  D. D. Giacomo,et al.  NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group , 2017, Leukemia.

[18]  S. Armstrong,et al.  NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis. , 2016, Cancer cell.

[19]  T. Cierpicki,et al.  Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). , 2016, Journal of medicinal chemistry.

[20]  Bo Wen,et al.  Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. , 2015, Cancer cell.

[21]  S. Raimondi,et al.  NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. , 2014, Blood.

[22]  R. Pieters,et al.  NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern , 2013, Leukemia.

[23]  R. Morgan,et al.  The role of HOX genes in normal hematopoiesis and acute leukemia , 2013, Leukemia.

[24]  K. Wagner,et al.  Analysis of NUP98/NSD1 translocations in adult AML and MDS patients , 2013, Leukemia.

[25]  Maksymilian Chruszcz,et al.  Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. , 2012, Blood.

[26]  Jolanta Grembecka,et al.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. , 2012, Nature chemical biology.

[27]  P. Aplan,et al.  NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights. , 2011, Blood.

[28]  R. Pieters,et al.  NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. , 2011, Blood.

[29]  Akihiko Yokoyama,et al.  Menin critically links MLL proteins with LEDGF on cancer-associated target genes. , 2008, Cancer cell.

[30]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[31]  G. Wang,et al.  NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis , 2007, Nature Cell Biology.

[32]  J. Hess,et al.  c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. , 2005, Blood.

[33]  Matthew Meyerson,et al.  The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.